SCHEMBL6824767

SCHEMBL6824767

Cc1[nH]c2ccc(Br)cc2c1C1=NCCN1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.53
HTR2C P28335 1/20 0.53
HTR7 P34969 1/20 0.53
HTR6 P50406 1/20 0.53
NISCH Q9Y2I1 7/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
CHUK O15111 1/20 0.40
MAPK1 P28482 1/20 0.40
HAVCR2 Q8TDQ0 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KIT P10721 1/20 0.39
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7727595 0.99 HTR2A (0.52) HTR2AHTR2CHTR7HTR6NISCH
SCHEMBL6824236 0.85 NISCH (0.50) NISCHLMNAKMT2AHSD17B10MAPT
Hydrochloric Acid SCHEMBL7736791 0.84 NISCH (0.49) NISCHLMNAKMT2AHSD17B10MAPT
SCHEMBL6824373 0.83 NISCH (0.55) HTR2AHTR2CHTR7HTR6NISCH
SCHEMBL6820911 0.83 HTR6 (0.53) HTR2AHTR2CHTR7HTR6LMNA
SCHEMBL30661856 0.83 HTR6 (0.53) HTR2AHTR2CHTR7HTR6LMNA
Hydrochloric Acid SCHEMBL7738726 0.82 NISCH (0.41) HTR2AHTR2CHTR7HTR6NISCH
Hydrochloric Acid SCHEMBL7736313 0.82 NISCH (0.54) HTR2AHTR2CHTR7HTR6NISCH
Hydrochloric Acid SCHEMBL7735637 0.80 MAOB (0.48) NISCHCHUKKMT2AKITL3MBTL1
Hydrochloric Acid SCHEMBL7736317 0.80 NISCH (0.55) HTR7HTR6NISCHLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
US-6410562-B1 ANTIDIABETIC AGENTS ELI LILLY AND COMPANY 2002-06-25 US disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R HTR2A 3670/4885HTR2C 3119/4885HTR7 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.